ZEPATIER (Merck Sharp & Dohme Corp.)
Welcome to the PulseAid listing for the ZEPATIER drug offered from Merck Sharp & Dohme Corp.. This Hepatitis C Virus NS5A Inhibitor [EPC],Breast Cancer Resistance Protein Inhibitors [MoA],HCV NS3/4A Protease Inhibitors [MoA],Hepatitis C Virus NS3/4A Protease Inhibitor [EPC],Breast Cancer Resistance Protein Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Merck Sharp & Dohme Corp. |
| NON-PROPRIETARY NAME: | elbasvir and grazoprevir |
| SUBSTANCE NAME: | ELBASVIR; GRAZOPREVIR ANHYDROUS |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Hepatitis C Virus NS5A Inhibitor [EPC],Breast Cancer Resistance Protein Inhibitors [MoA],HCV NS3/4A Protease Inhibitors [MoA],Hepatitis C Virus NS3/4A Protease Inhibitor [EPC],Breast Cancer Resistance Protein Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2016-01-28 |
| END MARKETING DATE: | 0000-00-00 |
ZEPATIER HUMAN PRESCRIPTION DRUG Details:
| Item Description | ZEPATIER from Merck Sharp & Dohme Corp. |
| LABELER NAME: | Merck Sharp & Dohme Corp. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 50; 100(mg/1; mg/1) |
| START MARKETING DATE: | 2016-01-28 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0006-3074_c26a08e8-ff71-4867-b547-3a3f384c6b90 |
| PRODUCT NDC: | 0006-3074 |
| APPLICATION NUMBER: | NDA208261 |
Other ELBASVIR; GRAZOPREVIR ANHYDROUS Pharmaceutical Manufacturers / Labelers:
